Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.46 |
| ▸ | ADH1C | P00326 | 1/20 | 0.46 |
| ▸ | ADH1A | P07327 | 1/20 | 0.46 |
| ▸ | ADH4 | P08319 | 1/20 | 0.46 |
| ▸ | ADH7 | P40394 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19600861 | 1.00 | TSHR (0.57) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL17623170 | 0.97 | — | — | |
| SCHEMBL16090692 | 0.90 | — | — | |
| Diethylamine SCHEMBL27825491 | 0.83 | TSHR (0.59) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL14733350 | 0.82 | TSHR (0.48) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Methoxymethane SCHEMBL2150575 | 0.81 | TSHR (0.77) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Methoxymethane SCHEMBL18954805 | 0.81 | TSHR (0.77) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Methoxymethane SCHEMBL2150128 | 0.81 | TSHR (0.77) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Methoxymethane SCHEMBL2149695 | 0.81 | TSHR (0.77) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL27454444 | 0.81 | TSHR (0.87) | TSHRALDH1A1EPHX1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121000-A1 | SOLID DOSAGE FORM FOR TRANSMUCOSAL DRUG DELIVERY | PRIMO PHARMATECH LLC (US) | 2023-04-20 | — | — | US | disclosed |
| CN-115605207-A | Solid dosage form for transmucosal administration | 葡默药物技术有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-11419769-B2 | Sublingual films | SUNOVION PHARMACEUTICALS INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220249465-A1 | UNIT DOSAGE FORM FOR TRANSMUCOSAL DRUG DELIVERY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | PRIMO PHARMATECH LLC (US) | 2022-08-11 | — | — | US | disclosed |
| CN-114007617-A | Unit dosage form for transmucosal administration of pharmaceutically active ingredients | 葡瑞慕生物技术有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3917502-A1 | METHODS OF TREATING A PATIENT HAVING PARKINSON'S DISEASE | Sunovion Pharmaceuticals Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021231860-A1 | SOLID DOSAGE FORM FOR TRANSMUCOSAL DRUG DELIVERY | PRIMO PHARMATECH LLC (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210322403-A1 | SUBLINGUAL APOMORPHINE | SUNOVION CNS DEVELOPMENT CANADA ULC (CA) | 2021-10-21 | — | — | US | disclosed |
| US-20210315882-A1 | METHODS OF TREATING A PATIENT HAVING PARKINSON'S DISEASE | SUNOVION PHARMACEUTICALS INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210205208-A1 | METHODS OF TREATING PARKINSON'S DISEASE BY ADMINISTRATION OF APOMORPHINE TO AN ORAL MUCOSA | SUNOVION CNS DEVELOPMENT CANADA ULC (CA) | 2021-07-08 | — | — | US | disclosed |
| US-20120082738-A1 | MUCOSAL FORMULATION | IZUN PHARMACEUTICALS CORPORATION (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120003292-A1 | ANTI-INFLAMMATORY DISSOLVABLE FILM | KALMAN, JONATHAN, MR. (IL) | 2012-01-05 | — | — | US | disclosed |
| US-8021696-B2 | Anti-inflammatory dissolvable film | IZUN PHARMACEUTICALS CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| WO-2010144817-A1 | SUBLINGUAL APOMORPHINE | ADAGIO PHARMACEUTICALS LTD. (CA) | 2010-12-16 | — | — | WO | disclosed |
| EP-2068900-A2 | FILM-DELIVERING RINSE | Izun Pharmaceuticals Corporation (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2046359-A1 | ANTI-INFLAMMATORY DISSOLVABLE FILM | Izun Pharmaceuticals Corporation (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080020027-A1 | Film-Delivering Rinse | IZUN PHARMACEUTICALS CORP. (US) | 2008-01-24 | — | — | US | disclosed |
| WO-2008011556-A2 | FILM-DELIVERING RINSE | IZUN PHARMACEUTICALS CORPORATION (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007149902-A1 | ANTI-INFLAMMATORY DISSOLVABLE FILM | IZUN PHARMACEUTICALS CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070292487-A1 | Anti-Inflammatory Dissolvable Film | IZUN PHARMACEUTICALS CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249465-A1 | UNIT DOSAGE FORM FOR TRANSMUCOSAL DRUG DELIVERY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | ABCG2, MUC1, SLC2A8 | TSHR 4032/4885ALDH1A1 1843/4885EPHX1 2512/4885 |
| US-20210322403-A1 | SUBLINGUAL APOMORPHINE | HTR5A, OPRL1, SNCA | TSHR 1408/4885ALDH1A1 1154/4885EPHX1 1221/4885 |
| US-20230121000-A1 | SOLID DOSAGE FORM FOR TRANSMUCOSAL DRUG DELIVERY | SLC10A2, MUC1, SLC46A1 | TSHR 2919/4885ALDH1A1 1101/4885EPHX1 2229/4885 |
| US-11419769-B2 | Sublingual films | SNCA, COMT, HTR5A | TSHR 241/4885ALDH1A1 2699/4885EPHX1 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.